BridgeBio Pharma, Inc. (BBIO)

How it makes money

BridgeBio generates revenue through three primary sources: (1) product sales from Attruby (acoramidis), which launched commercially in the United States in November 2024 following FDA approval, contributing $2.9 million in 2024; (2) non-refundable upfront payments and service revenue from exclusive licensing and collaboration agreements, primarily with Bayer for European commercialization and Kyowa Kirin for Japan, which generated $207.7 million in 2024; and (3) contingent milestone and royalty payments from commercial partners. The Bayer agreement includes an upfront payment of $135 million (received May 2024), potential regulatory milestones up to $150 million, potential sales milestones up to $450 million, and tiered royalties starting in the low-thirties percent on Bayer's net sales. Revenue is expected to transition from partnership-based upfront and milestone payments toward product sales as Attruby commercialization scales.

BridgeBio's competitive advantage is based on clinical differentiation of Attruby rather than structural moat elements. Attruby is the first and only approved product with a label specifying near-complete (≥90%) TTR stabilization, achieving superior cardiovascular outcomes compared to tafamidis and historical trial data. Clinical data demonstrated a 1.8 win ratio with statistical significance (p<0.0001) and showed benefit as early as month 3. However, the moat is narrow because competitors have existing TTR-stabilizing therapies in the market, and others are developing competing approaches. The advantage is product-specific rather than based on switching costs, network effects, or structural barriers. Long-term moat strength depends on maintaining clinical differentiation and successfully advancing the late-stage pipeline.

ATTR-CM demand is relatively defensive as the disease is progressive and fatal without treatment, creating steady patient demand regardless of economic cycles. The diagnosed ATTR-CM patient population is rapidly growing, increasing from fewer than 5,000 patients in 2019 to more than 50,000 patients in 2024, driven by expanded diagnostic capabilities and disease awareness. The total addressable market is estimated at $20.0 billion, with an estimated 400,000+ ATTR-CM patients in the U.S. and EU. The disease has a median life expectancy of two to five years from diagnosis if untreated, driving urgency for treatment initiation.

Key risks

• Drug Development and Clinical Uncertainty — Drug development is an inherently uncertain undertaking involving substantial risk. The company has limited operating history with Attruby just entering commercial phase. Clinical trials for pipeline candidates may fail to demonstrate adequate safety and efficacy, may experience enrollment delays, or may produce adverse safety signals. Earlier study results may not predict final trial outcomes.
• Regulatory and Foreign Approval Risk — The FDA may not accept data from clinical trials conducted outside the United States, potentially delaying or preventing approvals. Foreign regulatory approvals are not guaranteed even when U.S. approval is obtained. Ongoing regulatory compliance requirements and post-marketing obligations could require significant additional expense.
• Manufacturing and Supply Chain Dependency — The company is entirely dependent on third parties for manufacturing of all drug products. Manufacturing novel protein therapeutics and gene therapies is complex and difficult. Third parties may fail to provide sufficient quantities at acceptable quality levels or prices, or may experience manufacturing delays and supply disruptions.
• Market Acceptance and Commercial Uncertainty — Success depends on market acceptance by physicians, patients, and healthcare payors. The company's sales and marketing capabilities may prove ineffective. Reimbursement availability and pricing remain uncertain. Competitors have existing ATTR-CM treatments or may achieve regulatory approval of competing therapies before BridgeBio.
• Partner Concentration and Licensing Risk — The company is highly dependent on Bayer for European commercialization of Attruby. Revenue in 2024 was 93.6% derived from Bayer and Kyowa Kirin partnerships. Termination or underperformance of these licensing agreements could materially affect revenue and cash flow. BridgeBio may not successfully commercialize Attruby directly in the U.S. market.
• Capital Requirements and Funding Risk — The company has incurred significant debt with substantial interest payment obligations. Substantial additional capital funding is needed to support ongoing R&D, commercialization, and operations. The company's ability to raise capital through equity or debt financing is uncertain, particularly in adverse market conditions.

Top customers account for 93.6% of revenue

BridgeBio's 2024 revenue was heavily concentrated on two partnership agreements: Bayer (exclusive European commercialization of Attruby/Beyonttra) and Kyowa Kirin (Japan exclusive rights). These two partners generated $207.7 million of the company's $221.9 million total revenue in 2024 through upfront payments and service revenue recognition. Bayer alone received $135.0 million in upfront payments in May 2024, plus potential future milestone and royalty payments. The company's direct product sales of Attruby in the U.S. contributed only $2.9 million in 2024, as the product only launched commercially in November 2024.